Silexion Therapeutics shareholders vote down share capital increase and equity plan expansion

Silexion Therapeutics Corp

At reconvened EGM on March 23, 2026, quorum met with 1,216,369 shares (36.6% of outstanding).
Proposal to increase authorized shares from 9M to 59M failed: 38.2% for, 61.8% against.
Proposal to expand evergreen provision of 2024 equity plan to 10% fully diluted failed: 40.7% for, 59.3% against.
Neither proposal received the simple majority required for approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.